Cocrystal Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on April 24, 2025. The filing serves as a Regulation FD disclosure regarding a press release issued on the same date concerning the Company's norovirus oral antiviral candidate.
Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing discloses the issuance of a press release regarding the Company's norovirus oral antiviral candidate. No financial material changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing details on the norovirus candidate but does not include specific guidance, outlook, or risk commentary within the body of the 8-K. The document explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the specific clinical data or trial results regarding the norovirus oral antiviral candidate in the press release (Exhibit 99.1).
- Confirm the regulatory status and development timeline of the norovirus candidate.
- Review the Company's most recent periodic reports (10-K or 10-Q) for current financial position, as this 8-K contains no financial data.